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Anastrozole for prevention of breast cancer in high-risk 
postmenopausal women (IBIS-II): an international, 
double-blind, randomised placebo-controlled trial
Jack Cuzick, Ivana Sestak, John F Forbes, Mitch Dowsett, Jill Knox, Simon Cawthorn, Christobel Saunders, Nicola Roche, Robert E Mansel, 
Gunter von Minckwitz, Bernardo Bonanni, Tiina Palva, Anthony Howell, on behalf of the IBIS-II investigators*
Summary
Background Aromatase inhibitors eﬀ ectively prevent breast cancer recurrence and development of new contralateral 
tumours in postmenopausal women. We assessed the eﬃ  cacy and safety of the aromatase inhibitor anastrozole for 
prevention of breast cancer in postmenopausal women who are at high risk of the disease.
Methods Between Feb 2, 2003, and Jan 31, 2012, we recruited postmenopausal women aged 40–70 years from 
18 countries into an international, double-blind, randomised placebo-controlled trial. To be eligible, women had to be 
at increased risk of breast cancer (judged on the basis of speciﬁ c criteria). Eligible women were randomly assigned 
(1:1) by central computer allocation to receive 1 mg oral anastrozole or matching placebo every day for 5 years. 
Randomisation was stratiﬁ ed by country and was done with blocks (size six, eight, or ten). All trial personnel, 
participants, and clinicians were masked to treatment allocation; only the trial statistician was unmasked. The primary 
endpoint was histologically conﬁ rmed breast cancer (invasive cancers or non-invasive ductal carcinoma in situ). 
Analyses were done by intention to treat. This trial is registered, number ISRCTN31488319.
Findings 1920 women were randomly assigned to receive anastrozole and 1944 to placebo. After a median follow-up of 
5·0 years (IQR 3·0–7·1), 40 women in the anastrozole group (2%) and 85 in the placebo group (4%) had developed breast 
cancer (hazard ratio 0·47, 95% CI 0·32–0·68, p<0·0001). The predicted cumulative incidence of all breast cancers after 
7 years was 5·6% in the placebo group and 2·8% in the anastrozole group. 18 deaths were reported in the anastrozole 
group and 17 in the placebo group, and no speciﬁ c causes were more common in one group than the other (p=0·836).
Interpretation Anastrozole eﬀ ectively reduces incidence of breast cancer in high-risk postmenopausal women. This 
ﬁ nding, along with the fact that most of the side-eﬀ ects associated with oestrogen deprivation were not attributable to 
treatment, provides support for the use of anastrozole in postmenopausal women at high risk of breast cancer.
Funding Cancer Research UK, the National Health and Medical Research Council Australia, Sanoﬁ -Aventis, 
and AstraZeneca.
Introduction
Breast cancer is the most common form of cancer in 
women, with 1·4 million new cases reported worldwide in 
2008.1 Its incidence is rapidly increasing, largely because 
of an ageing population, rising socioeconomic status, 
increases in obesity, and several lifestyle changes, such as 
decreases in physical activity, later age at ﬁ rst childbirth, 
and reductions in breastfeeding. Although improvements 
in lifestyle are an important part of breast cancer prevention, 
as they are for cardiovascular disease, prophylactic treat-
ment is also likely to have an important role, especially for 
women at high risk (ie, 10-year risk of 5% or more).
Oestrogen is a key factor in breast cancer carcino-
genesis, and reductions in its synthesis can decrease 
breast cancer risk. Oestrogen production is driven by the 
aromatase enzyme, which converts androgens to 
oestrogens. Trials in the adjuvant setting have shown that 
aromatase inhibitors more eﬀ ectively prevent breast 
cancer recurrence2–4 and also development of new 
contralateral tumours3,5 in postmenopausal women than 
does tamoxifen. In a meta-analysis,6 tamoxifen and three 
other selective oestrogen receptor modulators were 
shown to reduce the frequency of oestrogen-receptor-
positive tumours by 51% overall, but no eﬀ ect was 
reported for oestrogen-receptor-negative tumours. The 
reduction in contralateral tumours has proved an 
important surrogate for the preventive eﬀ ects of 
tamoxifen6,7 and has been conﬁ rmed in a trial of the 
aromatase inhibitor exemestane,8 but whether this 
reduction extends to other agents is unclear.
One study of the preventive eﬀ ects of an aromatase 
inhibitor has been done in high-risk women without 
breast cancer: in the MAP.3 trial,8 exemestane was 
compared with placebo in postmenopausal women. 
Exemestane signiﬁ cantly reduced the incidence of all 
breast cancer by 53% and invasive breast cancer by 65% 
after a median follow-up of 3 years.8 No serious side-
eﬀ ects of exemestane were recorded, but median 
follow-up was fairly short for detection of any serious 
adverse events.8 Here, we report the ﬁ rst results from the 
International Breast cancer Intervention Study II 
(IBIS-II), in which the eﬃ  cacy and safety of the aromatase 
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inhibitor anastrozole for prevention of breast cancer are 
being compared with placebo.
Methods
Study design and participants
IBIS-II is an international, double-blind, randomised 
placebo-controlled trial. Between Feb 2, 2003, and Jan 31, 
2012, postmenopausal women aged 40–70 years were 
recruited in 153 centres in 18 countries (appendix). 
Women were deemed to be postmenopausal when they 
were aged 60 years or older; had had a bilateral 
oophorectomy; were younger than 60 years, but had a 
uterus and had had amenorrhoea for at least 12 months; 
or were aged less than 60 years, had no uterus, and had a 
concentration of follicle stimulating hormone of greater 
than 30 IU/L. Entry criteria were designed to include 
women aged 45–60 years who had a relative risk of breast 
cancer that was at least two times higher than in the 
general population, those aged 60–70 years who had a 
risk that was at least 1·5 times higher, and those aged 
40–44 years who had a risk that was four times higher. 
Full eligiblity criteria are listed in the appendix; to be 
eligible, women had to meet at least one of the criteria. 
Women who did not meet other eligibility criteria were 
included if the Tyrer-Cuzick model indicated a 10-year 
risk of breast cancer of more than 5%.9
Exclusion criteria were: premenopausal status; any 
previous diagnosis of breast cancer (except for oestrogen-
receptor-positive ductal carcinoma in situ diagnosed less 
than 6 months previously and treated by mastectomy); 
any invasive cancer in the previous 5 years (except for 
non-melanoma skin cancer or cervical cancer); present or 
previous use of selective oestrogen receptor modulators 
for more than 6 months (unless as part of IBIS-I and 
treatment was completed at least 5 years before study 
entry); intention to continue hormone replacement 
therapy; prophylactic mastectomy; evidence of severe 
osteoporosis (T score <–4 or more than two vertebral 
fractures); life expectancy of fewer than 10 years; 
psychologically or physiologically unﬁ t for the study; or a 
history of gluten or lactose intolerance, or both.
The trial was approved by the UK North West Multi-
centre Research Ethics Committee and was done in 
accordance with the Declaration of Helsinki, under the 
principles of good clinical practice. Participants provided 
written informed consent.
Randomisation and masking
Eligible women were randomly assigned (1:1) by central 
computer allocation to either anastrozole or matching 
placebo. Randomisation was stratiﬁ ed by country and 
was done with randomly chosen randomisation blocks 
(size six, eight, or ten) to maintain balance. All IBIS-II 
personnel, participants, and clinicians were masked to 
treatment allocation; only the trial statistician had access 
to unblinded data.
Procedures
Women received 1 mg oral anastrozole or matching 
placebo every day for 5 years. The primary endpoint was 
histologically conﬁ rmed breast cancer (invasive cancers 
or non-invasive ductal carcinoma in situ). Secondary 
endpoints were oestrogen-receptor-positive breast cancer, 
breast cancer mortality, other cancers, cardiovascular 
disease, fractures, adverse events, and deaths not due to 
breast cancer. 
Anastrozole group 
(n=1920)
Placebo group 
(n=1944)
Age (years) 59·5 (55·0–63·5) 59·4 (55·1–63·3)
Age at menarche (years) 13·0 (1·2–14·0) 13·0 (12·0–14·0)
Parous 1601 (83%) 1637 (84%)
Age at ﬁ rst child birth (years) 24·0 (21·0–27·0) 24·0 (21·0–27·0)
Age at menopause (years) 50·0 (45·0–52·0) 49·0 (45·0–52·0)
Height (cm) 162·0 (158·0–166·0) 162·2 (158·0–167·0)
Weight (kg) 71·8 (64·0–82·2) 72·1 (64·0–83·5)
Body-mass index (kg/m²)
<25 581 (30%) 568 (29%)
25–30 699 (36%) 732 (38%)
>30 640 (33%) 644 (33%)
Previous use of hormone replacement therapy 893 (47%) 910 (47%)
Use of hormone replacement therapy within previous 
12 months
128 (7%) 152 (8%)
Hysterectomy 631 (33%) 656 (34%)
Two or more ﬁ rst-degree or second-degree relatives with 
breast or ovarian cancer
956 (50%) 938 (48%)
One ﬁ rst-degree relative with breast cancer at age 50 years 
or younger
675 (35%) 653 (34%)
One ﬁ rst-degree relative with bilateral breast cancer 164 (9%) 141 (7%)
Lobular carcinoma in situ or atypical hyperplasia 154 (8%) 190 (10%)
Oestrogen-receptor-positive ductal carcinoma in situ 
treated by mastectomy within 6 months
160 (8%) 166 (9%)
10-year Tyrer-Cuzick risk (%) 7·6% (5·8–9·9) 7·8 (5·1–10·2)
Data are median (IQR) or n (%).
Table 1: Baseline characteristics
3864 women underwent randomisation
1920 assigned to anastrozole group
1914 received anastrozole
1944 assigned to placebo group
1937 received placebo
7 were ineligible
3 premenopausal
2 had previous diagnosis of breast cancer
1 ER-negative ductal carcinoma in situ
1 adopted*
6 were ineligible
3 premenopausal
2 had >2 spinal fractures
1 ER-negative ductal carcinoma in situ
Figure 1: Trial proﬁ le
ER=oestrogen receptor. *Could not give family history to establish whether high risk.
See Online for appendix
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Women visited local clinics at baseline, 6 months, and 
12 months, and then annually until the 5-year follow-up 
point. At baseline—after enrolment but before random-
isation—women had a mammogram and physical breast 
examination to exclude any pre-existing breast cancer, 
unless they had undergone these procedures within 
12 months before enrolment. Mammo grams were then 
done at least every 2 years. Women also had a dual energy 
x-ray absorptiometry scan and two spinal radiographs in 
the lateral dimensions at baseline to assess bone density, 
unless they had undergone these procedures within 
2 years before enrolment. Follow-up after 5 years varied 
and consisted of a mixture of clinic visits, annual 
questionnaires, and also record linkage systems in the 
UK. Blood samples were taken at baseline, after 1 year, 
and after 5 years for assessment of potential biomarkers. 
A detailed exploration of changes in bone mineral 
density, fractures, and use of bisphosphonates will be 
reported elsewhere.
Statistical analysis
Analyses were done on an intention-to-treat basis. A 
secondary per-protocol sensitivity analysis was done after 
some enrolled women were subsequently identiﬁ ed as 
ineligible. Initial assumptions for power calculation were 
based on an incidence of six cases of breast cancer per 
1000 women per year, and a compliance-adjusted 
reduction in incidence of breast cancer of 50% with 
anastrozole. This calculation led to a sample size of 
4000 women. However, interim ﬁ gures indicated that 
incidence of breast cancer was higher than predicted: the 
overall event rate was 6·6 cases of breast cancer per 
1000 women per year, which, with a 50% reduction in the 
anastrozole group, would translate to nine cases of breast 
cancer per 1000 women per year for placebo. Therefore, 
the sample size was reduced to 3500 women. The 
expected number of new cancers after a median of 
5 years of follow-up for a total trial size of 3500 women 
was 78 in the placebo group and 39 in the anastrozole 
group, leading to a power in excess of 90% for a 5% 
signiﬁ cance level.
Analyses of the eﬃ  cacy endpoints were based on 
hazard ratios (HRs). Cox proportional hazards 
models10,11 were used to derive HRs with 95% CIs. 
Survival curves were estimated with the Kaplan-Meier 
method.12 Results are presented for predeﬁ ned or 
common (aﬀ ecting at least 5% of participants) adverse 
events, or those for which a signiﬁ cant diﬀ erence 
between groups was recorded (with an α of 0·02). Side-
eﬀ ects and secondary endpoints were compared with 
relative risks. Adherence was calculated by the Kaplan-
Meier method, with censoring at breast cancer occur-
rence, death, 5 years of follow-up, or the cutoﬀ  date. 
Fisher’s exact tests were used to compare frequency of 
adverse events when appropriate. All p values were two 
sided. All analyses were done in Stata (version 12.1).
This trial is registered, number ISRCTN31488319.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. IS had full access to all the data in 
the study, and JC, JFF, and AH had ﬁ nal responsibility 
for the decision to submit for publication.
Results
3864 women underwent randomisation (ﬁ gure 1). 
Median age at entry was 59·5 years (IQR 55·0–63·5) 
and 695 (18%) were older than 65 years. 1803 women 
(47%) had previously used hormone replacement 
therapy, and 1287 (33%) had had a hysterectomy (table 1). 
1894 (49%) had two or more ﬁ rst-degree relatives who 
had had breast or ovarian cancer, and 1328 (34%) had 
one ﬁ rst-degree relative who had had breast cancer 
when aged 50 years or younger (table 1, appendix). 
326 women (8%) had been diagnosed with oestrogen-
receptor-positive ductal carcinoma in situ within the 
previous 6 months and been treated by mastectomy, and 
344 (9%) had a benign lesion with a diagnosis of lobular 
carcinoma in situ or atypical hyperplasia (table 1). 
13 women were shown to be ineligible after 
All invasive cancers
Invasive ER-positive cancers
Invasive ER-negative cancers
Ductal carcinoma in situ
All
0·1 0·2 0·5 1 2 5
Hazard ratio
Number of women Hazard ratio
(95% CI)
p value
Anastrozole
group 
(n=1920)
Placebo
group 
(n=1944)
32 (2%)
20 (1%)
11 (1%)
6 (<1%)
40 (2%)
64 (3%)
47 (2%)
14 (1%)
20 (1%)
85 (4%)
0·50 (0·32–0·76)
0·42 (0·25–0·71)
0·78 (0·35–1·72)
0·30 (0·12–0·74)
0·47 (0·32–0·68)
0·001
0·001
0·538
0·009
<0·0001
Figure 2: Analyses by type of breast cancer
Numbers in subgroups do not match totals because of missing data. ER=oestrogen receptor.
Number at risk
Placebo group
Anastrozole group
0
1944
1920
1
1927
1909
2
1645
1654
3
1445
1463
4
1241
1264
5
975
978
6
706
720
7
506
516
Time since randomisation (years)
0
5
10
Cu
m
ul
at
iv
e 
in
cid
en
ce
 (%
)
Placebo group
Invasive ER-positive cancers in placebo group
Anastrozole group
Invasive ER-positive cancers in anastrozole group
5·6%
3·3%
2·8%
1·4%
Figure 3: Cumulative incidence of all breast cancers and of invasive ER-positive breast cancers
ER=oestrogen receptor.
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randomisation (ﬁ gure 1) and were excluded from a 
secondary per-protocol analysis. No new cancers 
occurred in this group and the omission of these women 
did not change the results (data not shown).
The cutoﬀ  date for analysis was May 15, 2013. Median 
follow-up was 5·0 years (IQR 3·0–7·1). 19 399 women-
years of follow-up had been accrued (9727 in the anastrozole 
group vs 9672 in the placebo group). At the time of data 
Grade*
Low
Intermediate
High
Nodal status
Positive
Negative
Tumour size
≤10 mm
10–20 mm
>20 mm
Oestrogen-receptor status*
Positive
Negative
Progesterone-receptor status*
Positive
Negative
All
0·1 0·2 0·5 1 2 5
Hazard ratio
Hazard ratio
(95% CI)
ptrendNumber of women
Anastrozole group 
(n=1920)
Placebo group 
(n=1944)
7
16
9
12
18
11
8
13
20
11
9
15
32
8
29
26
16
44
19
28
17
47
14
28
22
64
0·86 (0·31–2·38)
0·55 (0·30–1·01)
0·35 (0·16–0·74)
0·75 (0·35–1·58)
0·41 (0·23–0·70)
0·58 (0·27–1·21)
0·28 (0·13–0·62)
0·76 (0·37–1·56)
0·42 (0·25–0·71)
0·78 (0·35–1·72)
0·32 (0·15–0·67)
0·68 (0·35–1·31)
0·50 (0·32–0·76)
0·01
0·08
0·1
0·08
0·2
Figure 4: Analyses by invasive breast cancer characteristics
Numbers in subgroups do not match totals because of missing data. *Assessed at local laboratories.
Age (years)
≤60
>60
Body-mass index (kg/m2)
<25
25–30
>30
Lobular carcinoma in situ or atypical hyperplasia
No
Yes
Ductal carcinoma in situ
No
Yes
Previous use of hormone replacement therapy
No
Yes
Less than 12 months before enrolment
All
0·2 0·5 1 2
Hazard ratio
Hazard ratio
(95% CI)
Number of women who developed  
breast cancer
7-year risk
in placebo
group*
Anastrozole group 
(n=1920)
Placebo group 
(n=1944)
4·1%
6·7%
4·7%
5·2%
6·9%
4·9%
12·1%
5·2%
9·7%
6·0%
5·3%
9·0%
20
20
10
14
16
35
5
34
6
17
23
3
0·47 (0·28–0·80)
0·46 (0·27–0·78)
0·43 (0·20–0·90)
0·49 (0·26–0·94)
0·47 (0·26–0·85)
0·52 (0·31–0·78)
0·31 (0·12–0·84)
0·47 (0·31–0·71)
0·44 (0·17–1·15)
0·36 (0·20–0·62)
0·61 (0·37–1·03)
0·30 (0·08–1·07)
44
41
23
28
34
66
19
72
13
47
38
12
Figure 5: Subgroup comparisons
*Cumulative risk calculated with Cox proportional hazards model.
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lock, 979 women (51%) in the anastrozole group and 975 
(50%) in the placebo group had completed 5 years of 
treatment. We estimated full 5-year adherence to be 68% 
in the anastrozole group versus 72% in the placebo group 
(p=0·0047; appendix). The main reasons for treatment 
discontinuation were adverse events (375 [20%] in the 
anastrozole group; 298 [15%] in the placebo group) and 
patient refusal (94 [5%] in the anastrozole group; 98 [5%] in 
the placebo group). At the cutoﬀ  date, 357 women (19%) in 
the anastrozole group and 450 (23%) in the placebo group 
were continuing with treatment.
Signiﬁ cantly more breast cancers (including ductal 
carcinoma in situ) were recorded during follow-up in the 
placebo group than in the anastrozole group (HR 0·47, 
95% CI 0·32–68; p<0·0001; ﬁ gure 2). The predicted 
cumulative incidence of all breast cancers after 7 years in 
the placebo group was double that in the anastro zole group 
(ﬁ gure 3), suggesting that 36 women (95% CI 33–44) 
would need to be treated with anastrozole to prevent one 
cancer in 7 years of follow-up. Invasive oestrogen-receptor-
positive tumours were also signiﬁ  cantly more common in 
the placebo group than in the anastrozole group 
(ﬁ gures 2, 3), but no signiﬁ cant beneﬁ t was recorded for 
invasive oestrogen-receptor-negative tumours (ﬁ gure 2). 
We noted no evidence of heterogeneity  for invasive 
cancers (p=0·3).
Anastrozole reduced frequency of high-grade tumours 
signiﬁ cantly more eﬀ ectively than it reduced frequency 
of low-grade tumours (ﬁ gure 4). We recorded no sig-
niﬁ cant heterogeneity in the eﬀ ect of anastrozole in 
diﬀ erent subgroups, but larger diﬀ erences were noted 
for oestrogen-receptor-positive, progesterone-receptor-
positive, and node-negative tumours (ﬁ gure 4). When 
models were adjusted for age, body-mass index, previous 
use of hormone replacement therapy, and smoking 
status, we recorded similar HRs as for univariate 
analyses (data not shown). Further details for ductal 
carcinoma in situ according to treatment allocation are 
shown in the appendix.
Further exploratory analyses did not show any hetero-
geneity according to subgroups divided by age, body-mass 
index, previous use of hormone replacement therapy, and 
ductal carcinoma in situ, although non-signiﬁ cantly larger 
eﬀ ects were recorded for women with lobular carcinoma 
in situ or atypical hyperplasia and those who had not 
previously used hormone replacement therapy (ﬁ gure 5). 
In the placebo group, the highest 7-year cumulative inci-
dences were recorded for lobular carcinoma in situ or 
atypical hyperplasia (12·1%), followed by ductal carcinoma 
in situ (9·7%), and none of these lesions (4·1%). 
35 deaths had been reported by data cutoﬀ  (table 2). No 
speciﬁ c causes were more common in one group than in 
the other (p=0·836; table 2). Overall frequency of cancers 
other than breast cancer was signiﬁ cantly higher in the 
placebo group than in the anastrozole group (table 3). 
Notably, gastrointestinal cancers (p=0·05) and skin 
cancers overall (p=0·05) were more common in the 
placebo group than in the anastrozole group (table 3).
Many adverse events were reported (table 4). Total 
number of fractures and number of fractures in speciﬁ c 
sites did not diﬀ er signiﬁ cantly by group (table 4). 
627 (16%) women were taking a bisphosphonate during 
the trial and concomitant use was similar between 
treatment groups (330 [17%] in anastrozole group vs 
297 [15%] in placebo group). Musculoskeletal adverse 
events were reported in signiﬁ cantly more women in the 
anastrozole group than in the placebo group (p=0·0001; 
table 4). We recorded no signiﬁ cant diﬀ erence between 
groups for mild (p=0·9) or severe (p=0·06) arthralgia, 
but moderate arthralgia was more common with anastro-
zole than with placebo (p=0·01; table 4). Carpal tunnel 
syndrome and joint stiﬀ ness were both signiﬁ  cantly 
more common in the anastrozole group than in the 
placebo group (table 4). Vasomotor symptoms were 
common in both groups, but signiﬁ cantly more frequent 
with anastrozole than placebo (p<0·0001; table 4). Signiﬁ -
cantly more women taking anastrozole than those taking 
placebo reported dry eyes (table 4). Vaginal or uterine 
Anastrozole group 
(n=1920)
Placebo group 
(n=1944)
Breast cancer 2 (<1%) 0
Other cancer 7 (<1%) 10 (1%)
Cerebrovascular accident or stroke 2 (<1%) 2 (<1%)
Cardiac arrest 3 (<1%) 1 (<1%)
Other 4 (<1%) 4 (<1%)
Total 18 (1%) 17 (1%)
Data are n (%).
Table 2: Causes of death
Anastrozole group 
(n=1920)
Placebo group 
(n=1944)
Risk ratio (95% CI)
Skin cancer 14 (1%) 27 (1%) 0·53 (0·28–0·99)
Non-melanoma 10 (1%) 20 (1%) 0·51 (0·24–1·08)
Melanoma 4 (<1%) 7 (<1%) 0·58 (0·17–1·97)
Gastrointestinal cancer 4 (<1%) 12 (1%) 0·34 (0·11–1·04)
Colorectal 3 (<1%) 11 (1%) 0·28 (0·08–0·99)
Endometrial cancer 3 (<1%) 5 (<1%) 0·61 (0·15–2·54)
Leukaemia, lymphoma, or myeloma 4 (<1%) 7 (<1%) 0·58 (0·17–1·97)
Thyroid cancer 0 2 (<1%) ··
Cancer of the urinary tract 2 (<1%) 5 (<1%) 0·41 (0·08–2·08)
Cancer of the nervous system 3 (<1%) 0 ··
Lung cancer 4 (<1%) 4 (<1%) 1·01 (0·25–4·04)
Ovarian cancer 4 (<1%) 7 (<1%) 0·58 (0·17–1·97)
Vaginal cancer 1 (<1%) 0 ··
Carcinomatosis 1 (<1%) 1 (<1%) 1·01 (0·06–16·18)
Total* 40 (2%) 70 (4%) 0·58 (0·39–0·85)
Data are n (%), unless otherwise stated. *p=0·005.
Table 3: Frequency of cancers other than breast cancer
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prolapse and vaginal pruritus were also signiﬁ  cantly 
reduced with anastrozole (table 4). Hypertension was 
signiﬁ cantly increased with anastrozole, but we recorded 
no signiﬁ cant diﬀ erences in frequencies of thrombo-
embolic events, cerebrovascular events, or myocardial 
infarction (table 4).
Discussion
We have shown that anastrozole substantially reduces 
incidence of breast cancer in the ﬁ rst 7 years of follow-up 
in women at high risk. Our results are similar to those 
recorded with exemestane in the MAP.3 trial.8 The 
reduction in incidence that we have reported is greater 
than that recorded for selective oestrogen receptor 
modulators such as tamoxifen.6 The eﬀ ect of tamoxifen 
has been shown to persist for at least 10 years,6,13 and 
further follow-up is needed to establish whether 
anastrozole has such a sustained eﬀ ect. We noted 
reductions in frequency of breast cancer in most 
subgroups of participants, although anastrozole’s eﬀ ect 
Anastrozole group (n=1920) Placebo group (n=1944) Risk ratio (95% CI)
Any 1709 (89%) 1723 (89%) 1·00 (0·98–1·03)
Fractures 164 (9%) 149 (8%) 1·11 (0·90–1·38)
Arm 66 (3%) 61 (3%) 1·10 (0·78–1·54)
Leg 65 (3%) 57 (3%) 1·15 (0·81–1·64)
Rib, spine, or collarbone 23 (1%) 18 (1%) 1·29 (0·70–2·39)
Pelvic or hip 9 (<1%) 10 (1%) 0·91 (0·37–2·24)
Skull 1 (<1%) 1 (<1%) 1·01 (0·06–16·18)
Musculoskeletal 1226 (64%) 1124 (58%) 1·10 (1·05–1·16)
Arthralgia* 972 (51%) 894 (46%) 1·10 (1·03–1·18)
Mild 385 (20%) 386 (20%) 1·01 (0·89–1·15)
Moderate 422 (22%) 363 (19%) 1·18 (1·04–1·33)
Severe 151 (8%) 123 (6%) 1·24 (0·99–1·56)
Joint stiﬀ ness 143 (7%) 96 (5%) 1·51 (1·17–1·94)
Pain in hand or foot 178 (9%) 147 (8%) 1·23 (0·99–1·51)
Carpal tunnel syndrome or nerve compression 67 (3%) 43 (2%) 1·58 (1·08–2·30)
Vasomotor*† 1090 (57%) 961 (49%) 1·15 (1·08–1·22)
Mild 550 (29%) 504 (26%) 1·10 (1·00–1·22)
Moderate 390 (20%) 330 (17%) 1·20 (1·05–1·37)
Severe 150 (8%) 127 (7%) 1·20 (0·95–1·50)
Gynaecological 460 (24%) 423 (22%) 1·10 (0·98–1·24)
Vaginal dryness 357 (19%) 304 (16%) 1·19 (1·03–1·37)
Haemorrhage or bleeding 65 (3%) 81 (4%) 0·82 (0·60–1·13)
Vaginal or uterine prolapse 13 (1%) 31 (2%) 0·42 (0·22–0·81)
Vulvovaginal pruritus 40 (2%) 60 (3%) 0·68 (0·45–1·00)
Vascular 152 (8%) 127 (7%) 1·27 (0·97–1·52)
Hypertension 89 (5%) 55 (3%) 1·64 (1·18–2·28)
Myocardial infarction or cardiac failure 8 (<1%) 9 (<1%) 0·90 (0·35–2·32)
Thrombosis or embolism 19 (1%) 17 (1%) 1·13 (0·59–2·17)
Phlebitis 9 (<1%) 8 (<1%) 1·14 (0·44–2·95)
Cerebrovascular accident 3 (<1%) 6 (<1%) 0·51 (0·13–2·02)
Eye 348 (18%) 335 (17%) 1·05 (0·92–1·21)
Dry eyes 83 (4%) 58 (2%) 1·45 (1·04–2·01)
Conjunctivitis 12 (1%) 5 (<1%) 2·43 (0·86–6·88)
Glaucoma 12 (1%) 24 (1%) 0·51 (0·25–1·00)
Cataract 90 (5%) 95 (5%) 0·96 (0·72–1·27)
Infections 230 (12%) 217 (11%) 1·07 (0·90–1·28)
Inﬂ uenza 25 (1%) 12 (1%) 2·11 (1·06–4·19)
Otitis media 18 (1%) 6 (<1%) 3·04 (1·21–7·64)
Data are n (%), unless otherwise stated. Details of any reported adverse event were recorded at every follow-up visit. Adverse events shown here are those that were 
predeﬁ ned, common (aﬀ ecting at least 5% of participants), or diﬀ ered signiﬁ cantly (p <0·02) between groups. *Assessments of severity broadly based on Common 
Terminology Criteria for Adverse Events, but some discretion used by clinicians. †Hot ﬂ ushes or night sweats.
Table 4: Adverse events of any severity reported at any time
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seemed to be increased in women with lobular carcinoma 
in situ or atypical hyperplasia. This increased eﬀ ect was 
also shown in two prevention trials of tamoxifen.14,15 An 
intriguing ﬁ nding in our study was that anastrozole’s 
eﬀ ect seemed to be greatest for high-grade tumours. 
Although highly signiﬁ cant, this ﬁ nding could have been 
a result of chance, because other indicators of aggressive 
or fast growing tumours (eg, node positivity and large 
tumour size) were not diﬀ erentially aﬀ ected.
As in MAP.3,8 we recorded no signiﬁ cant diﬀ erences 
between groups for cardiovascular events, but musculo-
skeletal and vasomotor symptoms were increased with 
anastrozole. Additionally, frequency of carpal tunnel 
syndrome was signiﬁ cantly higher with anastrozole, as 
was noted in the ATAC trial,16 although the disorder was 
still fairly rare. The high frequency of musculoskeletal and 
vasomotor symptoms in the placebo group is notable, 
because they are usually linked with an aromatase 
inhibitor in non-randomised comparisons.17 We have also 
conﬁ rmed an increase in frequency of hypertension with 
anastrozole, as was ﬁ rst reported in the ATAC trial.18
A new exploratory ﬁ nding is the signiﬁ cant increase in 
frequency of dry eyes with anastrozole, although the total 
number of events was small. Mixed ﬁ ndings relating to 
dry eyes in the menopause and hormone replacement 
therapy have been reported.19 Oestrogenic and androgenic 
receptors are located on corneal and conjunctival 
epithelia,19,20 but possible eﬀ ects of aromatase inhibitors 
on vision have been previously linked with retinal 
changes.21,22 We know of only two uncontrolled reports in 
which dry eyes have previously been associated with 
aromatase inhibitors.21,23 In one,23 sicca syndrome of the 
eyes and mouth was associated with anastrozole in 
patients with probable Sjögren’s syndrome. However, in 
our study, only four cases of Sjögren’s syndrome were 
reported—three with anastrozole and one with placebo. 
Further validation of the increased frequency of dry eyes 
in women taking an aromatase inhibitor is merited.
The reduced frequency of cancers other than breast 
cancer recorded in the anastrozole group is surprising, 
especially for colorectal cancers, in which hormone 
replacement therapy is known to be protective24 and for 
which the ATAC trial suggested a non-signiﬁ cant increase 
with anastrozole compared with tamoxifen in the adjuvant 
setting.3 Likewise, the reduction in non-melanoma skin 
cancer has not been reported previously with aromatase 
inhibitors, although the skin is known to be a site of 
aromatase activity.25 It is also interesting that incidence of 
endometrial cancer did not reduce, because increased 
oestrogen concentrations are a strong risk factor for this 
disease.26 Additionally, a substantially decreased risk of 
endometrial cancer with anastrozole was recorded in the 
ATAC trial,3 although the comparator was tamoxifen 
which is known to increase risk of endometrial cancer.14,27,28
Strengths of this study are the large number of breast 
cancer events recorded and the median follow-up of 
5 years, which is longer than for previous trials. Further 
follow-up is needed to fully assess the value of anastrozole 
in the prevention setting. Although a wide range of entry 
criteria were used in this trial, we recruited few women 
because of their breast density, which is a strong risk 
factor for the identiﬁ cation of high-risk women.29,30 
Establishment of whether an aromatase inhibitor is 
eﬀ ective in such a population is needed.
We have shown that anastrozole reduces the risk of 
invasive oestrogen-receptor-positive breast cancer and 
ductal carcinoma in situ by more than 50%, but that it has 
little eﬀ ect on oestrogen-receptor-negative cancers. The 
reported reductions are larger than are those reported for 
tamoxifen or raloxifene.5 Therefore, anastrozole is an 
attractive option for postmenopausal women at increased 
risk of breast cancer. Although many side-eﬀ ects recorded 
have been associated with oestrogen deprivation, they 
were only slightly more frequent in the anastrozole group 
than in the placebo group, indicating that most of these 
symptoms are not drug related. No additional side-eﬀ ects 
have been recorded with anastrozole after treatment 
completion in the adjuvant setting,3 which is likely to be 
true in the preventive setting as well.
Full adherence for 5 years was 70% overall and only 
slightly lower in the anastrozole group than in the 
placebo group. Overall adherence at 3 years was 75%, 
which is similar to that in the MAP.3 trial,8 which had 
85% overall adherence at 35 months. Adherence in our 
study was slightly better than for tamoxifen in IBIS-I,14 but 
our ﬁ ndings emphasise the need to understand and 
Panel: Research in context
Systematic review
We searched PubMed before our study began for reports published in English between 
Jan 1, 1980, and Dec 31, 2001. We used the search terms “breast cancer”, “prevention”, 
and “aromatase inhibitor”. We identiﬁ ed no other trials of breast cancer prevention with 
an aromatase inhibitor. However, we identiﬁ ed several adjuvant trials in which 
contralateral tumours were reported.5 Before the planned analysis, we used the same 
criteria to search PubMed again for reports published before May 30, 2013. Only one 
other prevention trial with exemestane had been reported,8 and updated or new results 
for contralateral tumours had been reported for some of the adjuvant trials. We also 
identiﬁ ed an overview of selective oestrogen receptor modulators for breast cancer 
prevention.6 Finally, we identiﬁ ed two large trials in which aromatase inhibitors are being 
assessed for prevention of ductal carcinoma in situ (ISRCTN37546358 and 
NCT00053898), but results have not been reported.
Interpretation
Overall, our data suggest that aromatase inhibitors are the most eﬀ ective agents available 
for breast cancer prevention. Follow-up in our trial was longer than that in the MAP.3 
prevention trial8 and adjuvant trials, and we recorded substantially more events. Equally 
important is the ﬁ nding that most side-eﬀ ects associated with oestrogen deprivation 
were not attributable to the treatment; most were also increased in the placebo group. 
Because anastrozole and exemestane have greater eﬃ  cacies than do tamoxifen and 
raloxifene, and have a diﬀ erent but generally decreased side-eﬀ ect proﬁ le, anastrozole or 
exemestane emerge as the treatments of choice for risk reduction in most 
postmenopausal women at high risk of breast cancer.
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minimise dropout. Dissemination of the fact that most 
side-eﬀ ects are not treatment related could help.
In the USA, the American Society of Clinical Oncology 
task force has recommended that exemestane be con-
sidered for prevention in addition to tamoxifen and 
raloxifene,31 and in the UK, the National Institute for 
Health and Care Excellence has recommended that 
tamoxifen and raloxifene be oﬀ ered to women at high 
risk of breast cancer.32 Our results strongly support the 
use of anastrozole for preventive treatment of high-risk 
post menopausal women (panel).
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